Asset
Navacaprant
Neumora Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04221230 | phase2 | completed | 2020-01-03 | 2022-04-08 | Neumora Therapeutics, Inc. | Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo |
| NCT06058013 | phase3 | completed | 2023-12-20 | 2026-05-06 | Neumora Therapeutics, Inc. | Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder |
| NCT06058039 | phase3 | completed | 2023-12-21 | 2026-05-04 | Neumora Therapeutics, Inc. | Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder |
| NCT06029439 | phase3 | active_not_recruiting | 2023-11-10 | 2027-06-01 | Neumora Therapeutics, Inc. | Study to Assess the Safety and Effectiveness of NMRA-335140-501 |
| NCT06029426 | phase3 | completed | 2023-09-20 | 2024-12-03 | Neumora Therapeutics, Inc. | Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder |
FDA applications (0)
This company has no applications containing this asset.